Host: |
Rabbit |
Applications: |
WB |
Reactivity: |
Human |
Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Short Description: |
Rabbit polyclonal antibody anti-CEACAM4 (36-155) is suitable for use in Western Blot research applications. |
Clonality: |
Polyclonal |
Conjugation: |
Unconjugated |
Isotype: |
IgG |
Formulation: |
PBS with 0.02% Sodium Azide, 50% Glycerol, pH7.3. |
Purification: |
Affinity purification |
Dilution Range: |
WB 1:500-1:1000 |
Storage Instruction: |
Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles. |
Gene Symbol: |
CEACAM4 |
Gene ID: |
1089 |
Uniprot ID: |
CEAM4_HUMAN |
Immunogen Region: |
36-155 |
Immunogen: |
Recombinant fusion protein containing a sequence corresponding to amino acids 36-155 of human CEACAM4 (NP_001808.2). |
Immunogen Sequence: |
FTIEALPSSAAEGKDVLLLA CNISETIQAYYWHKGKTAEG SPLIAGYITDIQANIPGAAY SGRETVYPNGSLLFQNITLE DAGSYTLRTINASYDSDQAT GQLHVHQNNVPGLPVGAVAG |
Tissue Specificity | Granulocytes. |
Post Translational Modifications | N-glycosylated. The cytoplasmic ITAM-like sequence becomes tyrosine phosphorylated by SRC family PTKs upon ligand-mediated receptor clustering and allows to initiate phagocytosis of bound ligand. |
Function | Granulocyte orphan receptor that acts as an trigger efficient phagocytosis of attached particles. |
Protein Name | Carcinoembryonic Antigen-Related Cell Adhesion Molecule 4Cea Cell Adhesion Molecule 4Carcinoembryonic Antigen Cgm7Non-Specific Cross-Reacting Antigen W236 |
Cellular Localisation | MembraneSingle-Pass Type I Membrane Protein |
Alternative Antibody Names | Anti-Carcinoembryonic Antigen-Related Cell Adhesion Molecule 4 antibodyAnti-Cea Cell Adhesion Molecule 4 antibodyAnti-Carcinoembryonic Antigen Cgm7 antibodyAnti-Non-Specific Cross-Reacting Antigen W236 antibodyAnti-CEACAM4 antibodyAnti-CGM7 antibody |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance